What is the all time high for CRISPR stock?
The all-time high CRISPR Therapeutics AG stock closing price was 210.04 on January 14, 2021. The CRISPR Therapeutics AG 52-week high stock price is 91.10, which is 64% above the current share price. The CRISPR Therapeutics AG 52-week low stock price is 37.55, which is 32.4% below the current share price.
What is the future price of Crispr stock?
The average price target is $80.47 with a high forecast of $112.00 and a low forecast of $30.00. The average price target represents a 32.64% change from the last price of $60.67.
What will CRSP stock be worth in 2025?
CRISPR Therapeutics AG Stock Prediction 2025
The CRISPR Therapeutics AG stock prediction for 2025 is currently $ 75.22, assuming that CRISPR Therapeutics AG shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a 34.02% increase in the CRSP stock price.
Is Crispr a buy hold or sell?
CRISPR Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 46 buy ratings, 27 hold ratings, and 6 sell ratings. What was the 52-week low for CRISPR Therapeutics stock? The low in the last 52 weeks of CRISPR Therapeutics stock was 37.60.
What is the CRISPR stock price forecast for 12 months?
CRISPR Therapeutics AG Stock Forecast
The 17 analysts with 12-month price forecasts for CRSP stock have an average target of 79.76, with a low estimate of 30 and a high estimate of 160. The average target predicts an increase of 37.61% from the current stock price of 57.96.
Where will CRISPR be in 10 years?
Over the next 10 years, we expect the biomedical applications of CRISPR to accelerate: A second wave of in vivo clinical trials including larger indications. Innovations enabling delivery of CRISPR to a greater variety of tissue.
Where will CRISPR be in 5 years?
In other words, 2024 should be a busy year for the company. The work it does throughout the next 12 months should help it lay a foundation for future major regulatory success beyond Casgevy. In the next five years, expect the company to earn approval for at least one more CRISPR-based gene editing treatment.
Why is CRSP price negative?
Sometimes you see negative stock prices in CRSP. This means that there was no closing price available for that period. Instead, the bid/ask average was used. To distinguish the bid/ask averages from actual closing prices, CRSP puts a leading dash in front of the price when the bid/ask average was used.
Does CRSP pay dividends?
There are no CRISPR Therapeutics AG dividends.
Who owns CRSP stock?
Institutional Ownership and Shareholders
Largest shareholders include ARK Investment Management LLC, Capital International Investors, ARKK - ARK Innovation ETF, T.
What Crispr company did Bill Gates invest in?
Our genius IT CEO Bill Gates and his friends decided to put their hands to “The Genesis Engine”, the new favorite of DNA editing in the lab, CRISPR. They poured $120 Million, as the title of this article said, into this project for a company named Editas Medicine, which lead the CRISPR to the world.
Should I buy CRSP stock now?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth prospects of CRSP, demonstrate its potential to underperform the market. It currently has a Growth Score of F.
Is CRSP profitable?
Full-Year Results. For 2023, CRISPR generated total revenues of $371.2 million, reflecting a substantial increase over the previous year's revenues of $1.2 million. Most of the 2023 total revenues comprised collaboration revenues from Vertex.
What is the CRISPR forecast for 2030?
The global CRISPR technology market is expected to reach USD 11,615 Million by 2030, at a CAGR of 20% during the forecast period 2021 to 2030.
Is CRISPR the future?
Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene-editing technology is the ideal tool of the future for treating diseases by permanently correcting deleterious base mutations or disrupting disease-causing genes with great precision and efficiency.
Has CRISPR ever been successful?
CRISPR gene-editing success for sickle cell raises new questions : Shots - Health News A Mississippi woman's life has been transformed by a treatment for sickle cell disease with the gene-editing technique CRISPR. All her symptoms from a disease once thought incurable have disappeared.
Has CRISPR ever worked?
“Clinical trial results demonstrate that CRISPR is safe, and it's effective for treating and curing human disease — an extraordinary advance given the technology is only 10 years old,” Doudna said at the conference in a video address.
How long until CRISPR is available?
It is a remarkable time for the development of CRISPR-based therapies. In late 2023, we saw the first-ever approval of CRISPR-based medicine: Casgevy, a cure for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
Will CRSP get FDA approval?
On Dec. 8, the FDA approved the first CRISPR gene editing drug developed by Crispr Therapeutics (CRSP) and Vertex Pharmaceuticals (VRTX) to treat sickle cell and beta thalassemia blood disorders.
Will CRISPR get FDA approval?
FDA Approves the First CRISPR Therapy for Sickle Cell Disease.
Is Crispr stock undervalued?
We maintain our positive outlook and fair value estimate of $119 per share. We view the stock as very undervalued, currently trading about 53% below our fair value estimate.
Is Crispr too expensive?
Casgevy, the first CRISPR therapy approved by the FDA, will cost $2.2 million, while a competing genetic medicine also cleared Friday is priced at $3.1 million. The first gene therapies for sickle cell disease may treat the inherited blood condition for many years, if not a lifetime.
How much cash does CRSP have?
Cash on Hand as of December 2023 : $1.69 B.
How often does Lockheed Martin pay dividends?
Lockheed Martin Corporation ( LMT ) pays dividends on a quarterly basis.
Does Pypl pay dividends?
Paypal Holdings (IT:1PYPL) does not pay a dividend.
